A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä

Biological Evaluation of Molecular Spherical Nucleic Acids: Targeting Tumors via a Hybridization-Based Folate Decoration




TekijätAuchynnikava, Tatsiana; Äärelä, Antti; Moisio, Olli; Liljenbäck, Heidi; Andriana, Putri; Iqbal, Imran; Laine, Toni; Palani, Senthil; Lehtimäki, Jyrki; Rajander, Johan; Salo, Harri; Airaksinen, Anu J.; Virta, Pasi; Roivainen, Anne

KustantajaAmerican Chemical Society (ACS)

Julkaisuvuosi2025

JournalACS Omega

Tietokannassa oleva lehden nimiACS Omega

Vuosikerta10

Numero6

Aloitussivu6003

Lopetussivu6014

eISSN2470-1343

DOIhttps://doi.org/10.1021/acsomega.4c10047

Verkko-osoitehttps://doi.org/10.1021/acsomega.4c10047

Rinnakkaistallenteen osoitehttps://research.utu.fi/converis/portal/detail/Publication/485203712


Tiivistelmä

Folate receptors (FRs), membrane-bound proteins that bind specifically to folate with high affinity, are overexpressed by various cancer types and are therefore used as targets for delivery of therapeutic agents. Molecular spherical nucleic acids (MSNAs) are dendritic formulations of oligonucleotides (ONs) that may have advantages over linear parent ONs with respect to delivery properties. Here, we assembled folate-decorated MSNAs, site-specifically radiolabeled them, and then biologically evaluated their effects in mice bearing HCC1954 breast cancer xenograft tumors. The biodistribution of intravenously administered 18F-radiolabeled MSNAs was monitored using positron emission tomography/computed tomography imaging. The results revealed higher accumulation of folate-decorated MSNAs in FR-expressing organs such as the liver, kidney, and spleen, as well as a higher tumor-to-muscle ratio than that observed for MSNAs without the folate decoration. However, the observed increase was statistically significant only for MSNA structures with a PO backbone. The observed selective uptake of folate-decorated MSNAs highlights their potential as targeted delivery vehicles for therapeutic and diagnostic agents in FR-overexpressing cancers.


Ladattava julkaisu

This is an electronic reprint of the original article.
This reprint may differ from the original in pagination and typographic detail. Please cite the original version.




Julkaisussa olevat rahoitustiedot
This research was supported by the Research Council of Finland (decision numbers 3089312, 343608, and 350117), Business Finland Ecosystem Project (448/31/2018), University of Turku Drug Research Doctoral Program, Turku University Foundation, and the Jane and Aatos Erkko Foundation.


Last updated on 2025-24-03 at 13:33